Compare BioNano Genomics Inc (BNGO) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Schlumberger NV — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Schlumberger NV trades at $52.85 (market cap $79.67B). The key difference: Schlumberger NV is far larger — about 5832.4× BioNano Genomics Inc's market cap, and Schlumberger NV pays a 2.2% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | SLB | |
|---|---|---|
Market Cap | $13.66M | $79.67B |
Sector | Health | Energy |
52-Week High | $4.92 | $58.01 |
52-Week Low | $1.06 | $31.72 |
Enterprise Value | $16.26M | $88.40B |
Dividend Yield | — | 2.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
SLB trades at $52.96, down 0.45% on the day, with a bullish technical signal from moving averages and oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.55, and maintains a consensus analyst price target of $63.00. Revenue for 2025 was $35.71 billion, with a net income margin of 8.53%, though margins have softened from prior years. Recent news highlights growth in digital and offshore segments, offset by Middle East challenges.
The outlook for SLB is positive, driven by earnings beats and robust analyst support, but risks include regional volatility and margin pressure. Upside potential exists if digital and production gains accelerate, yet investors must weigh debt levels and geopolitical headwinds against the stock's current valuation near 52-week highs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
